JP7167069B2 - キナーゼ阻害剤ならびに作製および使用のための方法 - Google Patents

キナーゼ阻害剤ならびに作製および使用のための方法 Download PDF

Info

Publication number
JP7167069B2
JP7167069B2 JP2019572355A JP2019572355A JP7167069B2 JP 7167069 B2 JP7167069 B2 JP 7167069B2 JP 2019572355 A JP2019572355 A JP 2019572355A JP 2019572355 A JP2019572355 A JP 2019572355A JP 7167069 B2 JP7167069 B2 JP 7167069B2
Authority
JP
Japan
Prior art keywords
pyrazol
piperidin
phenyl
carboxamide
picolinamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019572355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526498A (ja
JP2020526498A5 (https=
Inventor
バネッサ タイラー
ヤン チェン
ローズ イェン
Original Assignee
ライジェル ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライジェル ファーマシューティカルズ, インコーポレイテッド filed Critical ライジェル ファーマシューティカルズ, インコーポレイテッド
Publication of JP2020526498A publication Critical patent/JP2020526498A/ja
Publication of JP2020526498A5 publication Critical patent/JP2020526498A5/ja
Priority to JP2022171152A priority Critical patent/JP7379639B2/ja
Application granted granted Critical
Publication of JP7167069B2 publication Critical patent/JP7167069B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019572355A 2017-06-29 2018-06-28 キナーゼ阻害剤ならびに作製および使用のための方法 Active JP7167069B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022171152A JP7379639B2 (ja) 2017-06-29 2022-10-26 キナーゼ阻害剤ならびに作製および使用のための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762526838P 2017-06-29 2017-06-29
US62/526,838 2017-06-29
PCT/US2018/040021 WO2019006126A1 (en) 2017-06-29 2018-06-28 KINASE INHIBITORS AND METHODS OF MAKING AND USING THEM

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022171152A Division JP7379639B2 (ja) 2017-06-29 2022-10-26 キナーゼ阻害剤ならびに作製および使用のための方法

Publications (3)

Publication Number Publication Date
JP2020526498A JP2020526498A (ja) 2020-08-31
JP2020526498A5 JP2020526498A5 (https=) 2021-08-05
JP7167069B2 true JP7167069B2 (ja) 2022-11-08

Family

ID=62976284

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019572355A Active JP7167069B2 (ja) 2017-06-29 2018-06-28 キナーゼ阻害剤ならびに作製および使用のための方法
JP2022171152A Active JP7379639B2 (ja) 2017-06-29 2022-10-26 キナーゼ阻害剤ならびに作製および使用のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022171152A Active JP7379639B2 (ja) 2017-06-29 2022-10-26 キナーゼ阻害剤ならびに作製および使用のための方法

Country Status (6)

Country Link
US (3) US10590121B2 (https=)
EP (1) EP3645525A1 (https=)
JP (2) JP7167069B2 (https=)
CN (1) CN111032642B (https=)
CA (1) CA3068305A1 (https=)
WO (1) WO2019006126A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3068305A1 (en) * 2017-06-29 2019-01-03 Rigel Pharmaceuticals, Inc. Kinase inhibitors and methods for making and using
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
EP3898616B1 (en) 2018-12-20 2024-10-02 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
JP7676308B2 (ja) * 2018-12-20 2025-05-14 アムジエン・インコーポレーテツド Kif18a阻害剤として有用なヘテロアリールアミド
US11390604B2 (en) * 2019-03-08 2022-07-19 Hoffmann-La Roche Inc. Imidazole-pyrazole derivatives
WO2021018118A1 (en) * 2019-07-29 2021-02-04 Janssen Pharmaceutica Nv Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 1 proteins
US12540129B2 (en) 2019-08-02 2026-02-03 Amgen Inc. KIF18A inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021035257A1 (en) * 2019-08-21 2021-02-25 The Scripps Research Institute Monocyclic agonists of stimulator of interferon genes sting
CN110592056A (zh) * 2019-09-19 2019-12-20 昆明理工大学 噬菌体裂解酶复合粉剂及其制备方法和应用
CN114981259B (zh) * 2020-01-22 2024-06-18 豪夫迈·罗氏有限公司 新型杂环化合物
AR121717A1 (es) * 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
US20230295146A1 (en) * 2020-07-24 2023-09-21 The University Of Rochester Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
JP2024506021A (ja) * 2021-02-07 2024-02-08 エフ. ホフマン-ラ ロシュ アーゲー 新規ヘテロアリール置換イミダゾール誘導体
WO2022197575A1 (en) * 2021-03-17 2022-09-22 Merck Sharp & Dohme Llc Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2023088435A1 (zh) * 2021-11-19 2023-05-25 成都奥睿药业有限公司 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
JP2025513716A (ja) 2022-03-23 2025-04-30 ライジェル・ファーマシューティカルズ・インコーポレイテッド Irak阻害剤としてのピリミド-2-イル-ピラゾール化合物
AU2024214768A1 (en) * 2023-01-30 2025-08-07 The Johns Hopkins University 18 f-labeled pet radiotracers for imaging macrophage colony stimulating factor 1 receptor
CN118027009B (zh) * 2024-04-15 2024-07-12 北京师范大学 一类靶向于csf1r激酶的苯基酰胺类化合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016172560A1 (en) 2015-04-22 2016-10-27 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
WO2017009798A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
JP2017504595A (ja) 2013-12-13 2017-02-09 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
WO2017023941A1 (en) 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
EP0431519B1 (en) 1989-12-04 1994-06-15 G.D. Searle & Co. System for transdermal albuterol administration
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
JP2016505012A (ja) * 2013-01-10 2016-02-18 ニンバス アイリス, インコーポレイテッド Irak阻害剤およびその使用
CA3068305A1 (en) * 2017-06-29 2019-01-03 Rigel Pharmaceuticals, Inc. Kinase inhibitors and methods for making and using

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017504595A (ja) 2013-12-13 2017-02-09 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
WO2016172560A1 (en) 2015-04-22 2016-10-27 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
WO2017009798A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
WO2017023941A1 (en) 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds

Also Published As

Publication number Publication date
US11059814B2 (en) 2021-07-13
US20190002455A1 (en) 2019-01-03
EP3645525A1 (en) 2020-05-06
JP2020526498A (ja) 2020-08-31
JP7379639B2 (ja) 2023-11-14
US20200181135A1 (en) 2020-06-11
CN111032642B (zh) 2023-07-18
WO2019006126A1 (en) 2019-01-03
CN111032642A (zh) 2020-04-17
JP2023011726A (ja) 2023-01-24
US10590121B2 (en) 2020-03-17
US20210309655A1 (en) 2021-10-07
CA3068305A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
JP7379639B2 (ja) キナーゼ阻害剤ならびに作製および使用のための方法
JP7187729B2 (ja) Rip1阻害剤化合物並びにそれを製造及び使用するための方法
JP7339997B2 (ja) ベンズアゾール化合物ならびに該化合物の作製方法および使用方法
JP7379641B2 (ja) Irak阻害剤としてのピラゾールアミド化合物
EP4025572A1 (en) Heterocyclic rip1 kinase inhibitors
JP7379640B2 (ja) Irak阻害剤としての使用のためのオキサゾール誘導体およびその調製のための方法
WO2022192533A1 (en) Heterocyclic rip1 kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220519

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220928

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221026

R150 Certificate of patent or registration of utility model

Ref document number: 7167069

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150